Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Alemtuzumab for Multiple Sclerosis
Recruiting2 awardsPhase 1 & 2
Boston, Massachusetts
This trial is looking at the effect of a drug called alemtuzumab on microglial activation in patients with multiple sclerosis. They are testing the hypothesis that alemtuzumab reduces microglial activation, which may help with symptoms like cognitive fatigue.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.